<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01441635</url>
  </required_header>
  <id_info>
    <org_study_id>M12-663</org_study_id>
    <nct_id>NCT01441635</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids</brief_title>
  <official_title>Phase 2a Proof Of Concept Study to Evaluate the Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this proof-of-concept study is to determine whether elagolix (ABT-620) is safe
      and effective in the treatment of pre-menopausal women, 20 to 49 years of age, with heavy
      uterine bleeding associated with uterine fibroids. The effect of elagolix (ABT-620) on
      uterine size, fibroid size, and bleeding associated with uterine fibroids will be assessed
      versus placebo, and in combination with add-back therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Bleeding</measure>
    <time_frame>Day 1</time_frame>
    <description>The mean change from baseline to the last menstrual cycle during treatment in uterine blood loss.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Bleeding</measure>
    <time_frame>Month 3</time_frame>
    <description>The mean change from baseline to the last menstrual cycle during treatment in uterine blood loss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Bleeding Days</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from baseline to Month 3 in Number of Bleeding Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bleeding Days</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from baseline to Month 3 in Number of Bleeding Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Bleeding Scores</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from baseline to Month 3 in menstrual bleeding scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Menstrual Bleeding Scores</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from baseline to Month 3 in menstrual bleeding scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine Volume</measure>
    <time_frame>Day 1</time_frame>
    <description>Percent change from baseline to Month 3 in uterine volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uterine Volume</measure>
    <time_frame>Month 3</time_frame>
    <description>Percent change from baseline to Month 3 in uterine volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Concentration</measure>
    <time_frame>Day 1</time_frame>
    <description>Change from baseline to Month 3 in hemoglobin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Concentration</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from baseline to Month 3 in hemoglobin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation - Adverse event monitoring</measure>
    <time_frame>Up to month 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation - Vital signs</measure>
    <time_frame>2 months prior to dosing</time_frame>
    <description>Temperature, Blood Pressure and Pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation - Vital signs</measure>
    <time_frame>Day 1</time_frame>
    <description>Temperature, Blood Pressure and Pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation - Vital signs</measure>
    <time_frame>Month 1</time_frame>
    <description>Temperature, Blood Pressure and Pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation - Vital signs</measure>
    <time_frame>Month 2</time_frame>
    <description>Temperature, Blood Pressure and Pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation - Vital signs</measure>
    <time_frame>Month 3</time_frame>
    <description>Temperature, Blood Pressure and Pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation - Vital signs</measure>
    <time_frame>3 Months Post Dosing</time_frame>
    <description>Temperature, Blood Pressure and Pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations (complete or symptom directed)</measure>
    <time_frame>Up to 3 months prior to dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations (complete or symptom directed)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations (complete or symptom directed)</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations (complete or symptom directed)</measure>
    <time_frame>Month 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations (complete or symptom directed)</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead Electrocardiogram (ECG)</measure>
    <time_frame>Up to 3 months prior to dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead Electrocardiogram (ECG)</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-Lead Electrocardiogram (ECG)</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Biomarkers</measure>
    <time_frame>Day 1</time_frame>
    <description>Osteocalcin, CTX, P1NP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Biomarkers</measure>
    <time_frame>Month 3</time_frame>
    <description>Osteocalcin, CTX, P1NP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD)</measure>
    <time_frame>Up to 3 months prior to dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD)</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>up to 3 months prior to dosing</time_frame>
    <description>hematology, chemistry, urinalysis, lipid panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Day 1</time_frame>
    <description>hematology, chemistry, urinalysis, lipid panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Month 1</time_frame>
    <description>hematology, chemistry, urinalysis, lipid panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Month 2</time_frame>
    <description>hematology, chemistry, urinalysis, lipid panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests</measure>
    <time_frame>Month 3</time_frame>
    <description>hematology, chemistry, urinalysis, lipid panel</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Heavy Uterine Bleeding</condition>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Placebo Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose 1 plus estradiol/norethindrone acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose 1 plus estradiol/norethindrone acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose 2 plus estradiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose 2 plus estradiol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elagolix Dose 2 plus cyclical progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix Dose 2 plus cyclical progesterone</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix, elagolix sodium</intervention_name>
    <description>Elagolix Dose 1</description>
    <arm_group_label>Elagolix Dose 1</arm_group_label>
    <other_name>ABT-620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix, elagolix sodium</intervention_name>
    <description>Elagolix Dose 2</description>
    <arm_group_label>Elagolix Dose 2</arm_group_label>
    <other_name>ABT-620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix Dose 1 plus estradiol/norethindrone acetate</intervention_name>
    <description>Elagolix Dose 1 plus estradiol/norethindrone acetate</description>
    <arm_group_label>Elagolix Dose 1 plus estradiol/norethindrone acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix, elagolix sodium</intervention_name>
    <description>Elagolix Dose 3</description>
    <arm_group_label>Elagolix Dose 3</arm_group_label>
    <other_name>ABT-620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix, elagolix sodium</intervention_name>
    <description>Elagolix Dose 4</description>
    <arm_group_label>Elagolix Dose 4</arm_group_label>
    <other_name>ABT-620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix, elagolix sodium</intervention_name>
    <description>Elagolix Dose 5</description>
    <arm_group_label>Elagolix Dose 5</arm_group_label>
    <other_name>ABT-620</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix Dose 2 plus estradiol</intervention_name>
    <description>Elagolix Dose 2 plus estradiol</description>
    <arm_group_label>Elagolix Dose 2 plus estradiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix Dose 2 plus cyclical progesterone</intervention_name>
    <description>Elagolix Dose 2 plus cyclical progesterone</description>
    <arm_group_label>Elagolix Dose 2 plus cyclical progesterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is a pre-menopausal female â‰¥ 20 years of age.

          -  Subject has a diagnosis of uterine fibroids documented by a Pelvic Ultrasound.

          -  Subject has a history of regular menstrual cycles between 24 to 35 days.

          -  Subject has heavy uterine bleeding associated with uterine fibroids.

        Exclusion Criteria:

          -  Subject has had a myomectomy, uterine artery embolization, endometrial ablation or
             high intensity focused ultrasound for fibroid destruction within 1 year prior to
             randomization or any history of endometrial ablation.

          -  Subject has a history of osteoporosis or other metabolic bone disease.

          -  Subject shows evidence of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including
             depression), or neurologic diseases or any uncontrolled medical illness such as
             uncontrolled type 2 diabetes.

          -  Subject has a history of clinically significant condition(s) including but not limited
             to:

               -  Endometriosis

               -  Epilepsy or seizures

               -  Type 1 diabetes

               -  Any cancer (except basal cell carcinoma of the skin), including breast or ovarian
                  cancer or subject has taken any systemic cancer chemotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristof Chwalisz, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48144</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50273</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 66423</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50279</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 89654</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48139</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48148</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57881</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58906</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48142</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50275</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48103</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77573</name>
      <address>
        <city>Debary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77575</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 65924</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48163</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58482</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48140</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 51491</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58625</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48137</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48164</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48153</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54378</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57559</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54063</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57558</name>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <zip>55318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50272</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58622</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54369</name>
      <address>
        <city>Plainsboro</city>
        <state>New Jersey</state>
        <zip>08536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 59722</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 55109</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54368</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48146</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48156</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54389</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54375</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54372</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 50271</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48102</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58626</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57561</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54142</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 89653</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54377</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48158</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57402</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 77574</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48145</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48168</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 54370</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48160</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48149</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 91333</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 89661</name>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 90294</name>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2011</study_first_submitted>
  <study_first_submitted_qc>September 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <disposition_first_submitted>November 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 11, 2014</disposition_first_posted>
  <last_update_submitted>November 25, 2014</last_update_submitted>
  <last_update_submitted_qc>November 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elagolix</keyword>
  <keyword>Uterine Fibroids</keyword>
  <keyword>Elagolix sodium</keyword>
  <keyword>Leiomyomata</keyword>
  <keyword>Heavy Uterine Bleeding</keyword>
  <keyword>Menorrhagia</keyword>
  <keyword>ABT-620</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Norethindrone</mesh_term>
    <mesh_term>Norethindrone acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

